Compound libraries
Products
EBC main page
Search
Dyes
Impurities
Chemical probes
Contacts us
Pfizer reference compounds
Services
We provide 1 form of Bosutinib
Bosutinib
380843-75-4
|
530.446
|
5.087
Bosutinib is an antineoplastic agent used for the treatment of chronic, accelerated, or blast phase Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML) in adults with inadequate clinical response to other treatments. Compared to other tyrosine kinase inhibitors, it has a more favourable hematologic toxicity profile.
KIN001-160 | bosulif | bosutinib | ski 606
Bosutinib is an antineoplastic agent used for the treatment of chronic, accelerated, or blast phase Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML) in adults with inadequate clinical response to other treatments. Compared to other tyrosine kinase inhibitors, it has a more favourable hematologic toxicity profile.
KIN001-160 | bosulif | bosutinib | ski 606
$41/5 mg
(EBC)
1
We provide 0 compound for Bosutinib
Powered by Bioz